IMMUCELL CORP /DE/
IMMUCELL CORP /DE/ (ICCC): 3 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
11.6 months
D/E 0.51 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for IMMUCELL CORP /DE/across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$85.6M
Cash
$6.8M
Quarterly Burn
$2.7M
Runway
11.6 mo
Revenue
$10.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| first defense | Approved |
| immustaph latex agglutination kit | — |
| re-tain | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
23
Total value held
$8.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 520,654 | $3.3M |
| morgan stanley | 221,716 | $1.4M |
| renaissance technologies llc | 151,789 | $961K |
| geode capital management, llc | 65,765 | $416K |
| dimensional fund advisors lp | 56,030 | $355K |
| vanguard fiduciary trust co | 42,669 | $270K |
| northern trust corp | 41,618 | $263K |
| strategic financial services, inc. | 37,000 | $234K |
| citadel advisors llc | 35,696 | $226K |
| shufro rose & co llc | 35,000 | $222K |
Showing top 10 of 23 institutional holders of IMMUCELL CORP /DE/. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in IMMUCELL CORP /DE/'s pipeline?
IMMUCELL CORP /DE/ (ICCC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMMUCELL CORP /DE/'s lead drug candidate?
IMMUCELL CORP /DE/'s most advanced tracked candidate is first defense (Approved) for Neonatal calf diarrhea (scours).
What is IMMUCELL CORP /DE/'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IMMUCELL CORP /DE/ has approximately 11.6 months of cash runway.
What is IMMUCELL CORP /DE/'s market capitalization?
IMMUCELL CORP /DE/'s market capitalization is approximately $85.6M.
Who is the CEO of IMMUCELL CORP /DE/?
Mr. Paul F. Olivier Te Boekhorst is the chief executive officer of IMMUCELL CORP /DE/ (ICCC).
Get the full picture on IMMUCELL CORP /DE/
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.